EPB42

Across TCGA pan-cancer cohorts, EPB42 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EPB42 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher EPB42 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated EPB42 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where EPB42 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.910	0.703	.002	33	view →
PDAC	OS	Median	III,IV	0.537	1.000	.008	13	view →
LUAD	DFS	Tertile	III,IV	0.460	0.995	.013	7	view →
HNSC	OS	Quartile	All	0.932	0.793	.035	4	view →
GBM	OS	Tertile	All	0.934	0.740	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EPB42–CCRCC (DFS)

Open the CCRCC breakdown →